{"id":103595,"date":"2026-07-15T10:11:32","date_gmt":"2026-07-15T10:11:32","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/103595\/"},"modified":"2026-07-15T10:11:32","modified_gmt":"2026-07-15T10:11:32","slug":"ubs-stays-positive-on-astrazeneca-ahead-of-second-quarter-results-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/103595\/","title":{"rendered":"UBS stays positive on AstraZeneca ahead of second-quarter results"},"content":{"rendered":"

\"UBS<\/a> UBS stays positive on AstraZeneca ahead of second-quarter results Proactive uses images sourced from Shutterstock <\/p>\n

UBS expects AstraZeneca PLC (LSE:AZN, NASDAQ:AZN)<\/a>\u00a0to report solid second-quarter results later this month, though it sees little room for the drugmaker to raise full-year guidance. <\/p>\n

The bank reiterated its ‘buy’ rating on Britain’s second most valuable listed company, ahead of results due on 27 July. <\/p>\n

UBS set a 12-month price target of 17,600p, well above the 12,734.87p at which the shares closed on 10 July. <\/p>\n

The forecasts sit broadly in line with consensus, running about 1% below on sales and 2% below on core operating profit and earnings for the quarter. <\/p>\n

The bank expects the sharpest investor focus to fall on AstraZeneca’s target of $80 billion in annual revenue by 2030, a\u00a0goal that has come under scrutiny after the recent failure of Wainua in a form of heart disease<\/a>. <\/p>\n

UBS said it still viewed the 2030 target as achievable, pointing to blockbuster trial readouts due in 2027, including an oral cholesterol treatment and a cell therapy for multiple myeloma. <\/p>\n

The bank was more cautious on nearer-term readouts, flagging higher risk around lung and breast cancer trials expected in the second half. <\/p>\n

It named late-stage data on the lung cancer treatment tozorakimab in chronic obstructive pulmonary disease as a key September event. <\/p>\n

UBS forecasts full-year revenue of around $63.3 billion, up from $58.7 billion in 2025. <\/p>\n

It expects core earnings per share of $9.48, rising to $11.38 in 2027. <\/p>\n

The bank sees the core operating margin widening to 33.6% this year from 31.5% in 2025. <\/p>\n

UBS said it did not expect AstraZeneca to lift its full-year guidance, with its own forecasts already sitting solidly within the current range. <\/p>\n

It described the company as having the broadest late-stage pipeline in the sector, while acknowledging that remaining catalysts this year carried higher risk. <\/p>\n

UBS makes a market in AstraZeneca securities and holds a long position of 0.5% or more in its shares. <\/p>\n","protected":false},"excerpt":{"rendered":"UBS stays positive on AstraZeneca ahead of second-quarter results Proactive uses images sourced from Shutterstock UBS expects AstraZeneca…\n","protected":false},"author":2,"featured_media":103596,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[129],"tags":[14607,223],"class_list":["post-103595","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ubs","tag-astrazeneca","tag-ubs"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116923458092423525","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/103595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=103595"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/103595\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/103596"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=103595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=103595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=103595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}